Alumis Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Martin Babler
- Full Time Employees
- 237
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 280 East Grand Avenue South San Francisco CA United States of America 94080
- IPO Date
- Jun 28, 2024
- CIK
- 0001847367
- Website
- alumis.com
- Similar Companies
- Business
- Alumis Inc is a clinical-stage biopharmaceutical company focused on developing oral therapies for immune-mediated diseases. The company specializes in precision oral small molecule inhibitors targeting tyrosine kinase 2 (TYK2) pathways, with its core products including ESK-001, an oral, highly selective allosteric TYK2 inhibitor in Phase 3 clinical trials for moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005, a CNS-penetrant allosteric TYK2 inhibitor in development for neuroinflammatory and neurodegenerative diseases such as multiple sclerosis. Alumis also pursues additional pipeline candidates with applications across autoimmune and inflammatory conditions. The company operates primarily in the United States and targets markets within the biopharmaceutical and healthcare sectors. Founded in 2018, Alumis is headquartered in California. In recent major developments, Alumis announced a strategic all-stock merger agreement with Acelyrin, Inc., expected to close in the second quarter of 2025, which will combine cash and drug pipelines under the Alumis name, creating a larger immunology and inflammation-focused entity with an enhanced cash position of over $700 million to extend its operational runway through 2027. Alumis has advanced its clinical programs with key milestones anticipated, including Phase 3 topline data for ESK-001 in psoriasis expected in early 2026 and Phase 2b data for its lupus program in 2026, alongside a planned initiation of Phase 2 clinical trials for A-005 in multiple sclerosis during the first half of 2026. The company also reports collaboration revenue from partnerships like Kaken Pharmaceutical and has seen substantial investment activity by insiders signaling confidence in its strategic growth. These activities highlight Alumis' shifting focus towards late-stage clinical development and broader immunology market expansion.
Company News
Alumis to Participate in Upcoming September Investor Conferences
Alumis: A Brutal Lupus Setback, But Psoriasis Still Supports Upside
Alumis Inc. (ALMS) Discusses Phase IIb LUMUS Trial Results and Subgroup Insights in Type 1 Interferon-Driven Diseases Transcript
Alumis Lupus Trial Misses Main Goals, but High-Interferon Subgroup Shows Promise
Alumis eyes late-stage lupus study despite trial miss
Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)
Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements
California State Teachers Retirement System Raises Stock Position in Alumis Inc. $ALMS
4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
Alumis Psoriasis Treatment Shows Leading Skin Clearance Rates
Alumis (NASDAQ:ALMS) Shares Up 5.7% – What’s Next?
Alumis: Is Envudeucitinib The 'Real Deal?' We Should Find Out Soon
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back
Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements
Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug
Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis
Alumis: Oral Psoriasis Med Can Win Approval, Challenge Big Pharma In Major Markets
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements